Pittsboro based biotech startup is sold to Japanese firm for $175M
Startup biotech Propella Therapeutics is being acquired by Japan-based Astella Pharma in a deal valued at $175 million. Here are the details.
Read More
prostate cancer
Levee Medical raising $4.3 million to support prostate cancer recovery
DURHAM — Levee Medical, Inc. last week filed with the SEC for their second major round of funding. According to the document the company has raised more than $3.4 million in debt from 34 investors. The company aims to raise a total of $4.3 million, with more than $850,000...
Read More
Why are Black men more susceptible to prostate cancer? Duke researchers find clues
Genetic studies usually recruit non-Hispanic white men, despite data showing that Black men are disproportionately affected by prostate cancer and more than twice as likely to die from the disease compared to their white counterparts. A new Duke study may help address that problem.
Read More
Durham startup targeting an implant targeting prostate cancer recovery raises $6.6M
A Durham startup focusing on improving outcomes from prostate cancer surgery now has $6.6 million in its tool chest to further advance its research and development.
Read More
Duke researchers lay out new strategy for fighting prostate cancer
Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new therapeutic approach.
Read More
Chapel Hill cancer drug startup Sisu Pharma raises $1.7M, wants $2.3M more
Founded y Duke University professors, Sisu Pharma is developing drugs to treat prostate cancer in patients who have exhausted all therapeutic options.
Read More
Duke researchers discover possible breakthrough therapy for those with advanced prostate cancer
The researchers identified a cell surface receptor that is essential for the function and survival of resistant prostate cancer cells, and showed in laboratory studies that this receptor can be targeted to halt tumor growth.
Read More
